These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17136978)

  • 1. Clinical efficacy of OM-85 BV in COPD and chronic bronchitis: a systematic review.
    Sprenkle MD; Niewoehner DE; MacDonald R; Rutks I; Wilt TJ
    COPD; 2005 Mar; 2(1):167-75. PubMed ID: 17136978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of OM-85 BV in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis.
    Pan L; Jiang XG; Guo J; Tian Y; Liu CT
    J Clin Pharmacol; 2015 Oct; 55(10):1086-92. PubMed ID: 25903441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease.
    Solèr M; Mütterlein R; Cozma G;
    Respiration; 2007; 74(1):26-32. PubMed ID: 16772707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of OM-85 in Patients with Chronic Bronchitis and/or Chronic Obstructive Pulmonary Disease.
    Tang H; Fang Z; Saborío GP; Xiu Q
    Lung; 2015 Aug; 193(4):513-9. PubMed ID: 26044556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacterial lysates (OM-85 BV): a cost-effective proposal in order to contrast antibiotic resistance.
    Troiano G; Messina G; Nante N
    J Prev Med Hyg; 2021 Jun; 62(2):E564-E573. PubMed ID: 34604601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease.
    Teo E; House H; Lockhart K; Purchuri SN; Pushparajah J; Cripps AW; van Driel ML
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010010. PubMed ID: 25201571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic impact of using an immunostimulating agent to prevent severe acute exacerbations in patients with chronic obstructive pulmonary disease.
    Collet JP; Ducruet T; Haider S; Shapiro S; Robinson A; Renzi PM; Contandriopoulos AP; Ernst P
    Can Respir J; 2001; 8(1):27-33. PubMed ID: 11223497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preventive treatment of chronic bronchitis: a meta-analysis of clinical trials with a bacterial extract (OM-85 BV) and a cost-effectiveness analysis.
    Bergemann R; Brandt A; Zoellner U; Donner CF
    Monaldi Arch Chest Dis; 1994 Sep; 49(4):302-7. PubMed ID: 8000415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with OM-85 BV in upper and lower respiratory tract infections.
    Derenne JP; Delclaux B
    Respiration; 1992; 59 Suppl 3():28-31. PubMed ID: 1439237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial.
    Beeh KM; Beier J; Candler H; Wittig T
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2877-2884. PubMed ID: 27920515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral purified bacterial extracts in chronic bronchitis and COPD: systematic review.
    Steurer-Stey C; Bachmann LM; Steurer J; Tramèr MR
    Chest; 2004 Nov; 126(5):1645-55. PubMed ID: 15539739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease.
    Poole P; Chong J; Cates CJ
    Cochrane Database Syst Rev; 2015 Jul; (7):CD001287. PubMed ID: 26222376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of OM-85 in managing respiratory tract infections in China.
    Xuan J; Wang L; Yin H; Xuan D; Zhou Y; Hu S
    J Med Econ; 2015 Mar; 18(3):167-72. PubMed ID: 25275426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Preventive effect of an immunomodulator, OM-85 BV, on acute exacerbations of chronic bronchitis in elderly patients. Preliminary results at six months in 291 patients].
    Orcel B; Delclaux B; Baud M; Derenne JP
    Rev Mal Respir; 1993; 10(1):23-8. PubMed ID: 8451491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).
    Herath SC; Poole P
    Cochrane Database Syst Rev; 2013 Nov; (11):CD009764. PubMed ID: 24288145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review and meta-analysis of prophylactic antibiotics in COPD and/or chronic bronchitis.
    Lee JS; Park DA; Hong Y; Jo KW; Lee SW; Huh JW; Oh YM; Lee SD
    Int J Tuberc Lung Dis; 2013 Feb; 17(2):153-62. PubMed ID: 23317949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant.
    Collet JP; Shapiro P; Ernst P; Renzi T; Ducruet T; Robinson A
    Am J Respir Crit Care Med; 1997 Dec; 156(6):1719-24. PubMed ID: 9412546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis.
    Cazzola M; Calzetta L; Page C; Rogliani P; Matera MG
    Pulm Pharmacol Ther; 2018 Feb; 48():185-194. PubMed ID: 29233650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Broncho-Vaxom (OM-85) on the frequency of chronic obstructive pulmonary disease (COPD) exacerbations.
    Choi JY; Park YB; An TJ; Yoo KH; Rhee CK
    BMC Pulm Med; 2023 Oct; 23(1):378. PubMed ID: 37805515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotics for exacerbations of chronic obstructive pulmonary disease.
    Vollenweider DJ; Jarrett H; Steurer-Stey CA; Garcia-Aymerich J; Puhan MA
    Cochrane Database Syst Rev; 2012 Dec; 12():CD010257. PubMed ID: 23235687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.